India Keytruda Market: Is "Early Intervention" the 2026 Game-Changer? A defining 2026 milestone in the industry is the shift toward Neoadjuvant and Adjuvant usage. In 2026, the market is identifying a trend where Keytruda is used before surgery to shrink tumors (neoadjuvant) or after surgery (adjuvant) in lung and melanoma cases. This 2026 strategy is vital because it moves the drug from being a "last resort" for metastatic patients to a "curative-intent" tool...
0 Acciones
9 Views
0 Vista previa